Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
RNA interference in cervical cancer produces increased sensitivity to cisplatin
December 22nd, 2005
According to recent research from Australia published in the journal Molecular Pharmacology, RNA interference (RNAi) against human papillomavirus (HPV) oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. "Targeted inhibition of oncogenes in tumor cells is a rational approach toward the development of cancer therapies based on RNAi," wrote L.N. Putral and colleagues, University of Queensland. "Tumors caused by HPV infection are an ideal model system for RNAi-based cancer therapies because the oncogenes that cause cervical cancer, E6 and E7, are expressed only in cancerous cells." The researchers...
Source: Women's Health Weekly (2005-12-22)
|
